Gritstone bio

Gritstone bio is a pioneering brand that specializes in developing next-generation vaccines for cancer and infectious diseases. With a focus on leveraging the immune system's ability to recognize and destroy diseased cells, Gritstone's approach aims to generate a therapeutic immune response by targeting select antigens. Initially, their focus was on tumor-specific neoantigens, but they have also expanded their programs to include viral antigens displayed on the surface of virally infected cells.

By activating and directing the immune system to these targets, Gritstone believes they can extend the benefits of immunotherapy to more patients. The brand is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. Gritstone was founded in 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Their experienced leadership team spans multiple disciplines, including immunotherapy research, genomics and bioinformatics, clinical and regulatory development, and biomanufacturing. With their innovative approach and expertise, Gritstone bio is at the forefront of revolutionizing cancer and infectious disease treatments